Trial changes, page-35

Yes Hottuna..that was the presentation at the AHA on 14/11/2011.

This is what Dr Perin (Principal Investigator - Texas Heart Institute) said at the time (MSB release dated 14/15 Nov 2011):

"These clinical findings are the first using any cell therapy in heart failure to show a concordant positive effect on clinical outcomes, cardiac remodelling, and functional capacity,the three key parameters in congestive heart failure. Together they indicate that a single 150million dose of Revascor may significantly reduce both heart failure hospitalizations and death in these very sick patients who have such poor prognosis despite maximal existing therapies".
"Based on their defined product characterization, batch to batch consistency, immediate availability, and lack of relevant immunogenicity, MPC's appear to be the an ideal cell type to provide a new level of care in congestive heart failure. we look forward to progressing the Revascor Clinical program into Phase 3".

Four years on and the P3 trials now available at 93 locations ( 50+ recruiting)....